INBX
Inhibrx Biosciences, Inc. NASDAQ Listed Jun 4, 2024$93.05
-1.22%
vs $94.20
Mkt Cap $1.4B
52w Low $14.27
61.8% of range
52w High $141.84
50d MA $104.53
200d MA $75.06
P/E (TTM)
-10.3x
EV/EBITDA
—
P/B
180.3x
Debt/Equity
13.4x
ROE
-1752.2%
P/FCF
-11.1x
RSI (14)
32.90
ATR (14)
$6.37
Beta
1.83
50d MA
$104.53
200d MA
$75.06
Avg Volume
435.0K
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
11025 North Torrey Pines Road · La Jolla, CA 92037 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -2.08 | -2.11 | -1.4% | 64.87 | -1.5% | -6.1% | +6.1% | -2.3% | +5.3% | -1.0% | — |
| Nov 14, 2025 | AMC | -2.08 | -2.28 | -9.6% | 79.13 | +0.0% | -2.2% | +0.3% | +5.9% | -2.8% | +5.1% | — |
| Aug 13, 2025 | AMC | -2.92 | -1.85 | +36.6% | 23.57 | +2.0% | +1.6% | -2.5% | +2.3% | -3.6% | +6.1% | — |
| May 14, 2025 | AMC | -2.55 | -2.80 | -9.8% | 10.84 | +1.2% | +10.9% | +2.6% | +1.1% | +4.8% | +0.7% | — |
| Mar 17, 2025 | AMC | -2.88 | -3.09 | -7.3% | 13.94 | -2.9% | +0.4% | +0.0% | +0.7% | +1.8% | +2.6% | — |
| Nov 14, 2024 | AMC | -3.06 | -2.84 | +7.2% | 14.33 | +0.0% | -3.5% | -1.5% | +4.9% | -1.7% | -0.4% | — |
| Aug 13, 2024 | AMC | -3.60 | 125.48 | +3585.6% | 11.30 | -0.3% | -0.1% | +9.8% | +0.5% | +3.9% | -0.3% | — |
| Jun 3, 2024 | AMC | -1.04 | -1.44 | -38.5% | 18.02 | +2.4% | -4.5% | -1.9% | -3.8% | +2.5% | -0.4% | — |
| Feb 28, 2024 | AMC | -1.07 | -1.73 | -61.7% | 37.00 | -0.1% | -1.0% | -0.5% | -2.2% | -0.2% | +0.4% | — |
| Nov 9, 2023 | AMC | -1.01 | -1.10 | -8.9% | 18.30 | +1.0% | +4.4% | +3.1% | +2.7% | +0.2% | +3.7% | — |
| Aug 7, 2023 | AMC | -1.02 | -1.08 | -5.9% | 19.32 | -0.1% | -12.0% | -7.4% | +1.0% | +0.3% | +0.8% | — |
| May 8, 2023 | AMC | -0.84 | -1.12 | -33.3% | 26.45 | -2.8% | -0.5% | -1.7% | -3.1% | -1.4% | +1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 22 | JMP Securities | Maintains | Market Perform → Market Perform | — | $24.16 | $24.45 | +1.2% | +3.5% | +0.2% | +3.5% | +5.7% | +1.8% |
| May 15 | JMP Securities | Maintains | Market Perform → Market Perform | — | $10.84 | $10.97 | +1.2% | +10.9% | +2.6% | +1.1% | +4.8% | +0.7% |
| Mar 18 | Citizens Capital Markets | Maintains | Market Perform → Market Perform | — | $13.94 | $13.53 | -2.9% | +0.4% | +0.0% | +0.7% | +1.8% | +2.6% |
| Jan 22 | JMP Securities | Maintains | Market Perform → Market Perform | — | $14.19 | $14.01 | -1.3% | -4.2% | -3.7% | +0.5% | -5.6% | -1.4% |
| Jan 23 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $33.33 | $35.50 | +6.5% | +8.9% | -0.1% | +3.4% | +0.3% | +1.1% |
| Nov 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.29 | $22.44 | +0.7% | -0.1% | -11.2% | +3.9% | +0.0% | -1.0% |
| Aug 23 | JMP Securities | Maintains | Outperform → Outperform | — | $19.06 | $19.09 | +0.2% | +2.0% | -3.5% | -3.5% | +6.9% | +13.3% |
| May 10 | JMP Securities | Maintains | Market Outperform → Outperform | — | $26.31 | $26.29 | -0.1% | -1.7% | -3.1% | -1.4% | +1.7% | -1.6% |
| Mar 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.97 | $23.88 | -0.4% | -2.6% | -2.5% | -5.7% | +6.3% | +3.4% |
| Mar 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $23.69 | $22.76 | -3.9% | +1.2% | -2.6% | -2.5% | -5.7% | +6.3% |
| Nov 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $29.08 | $29.51 | +1.5% | +2.0% | -2.2% | +11.0% | +1.6% | +0.3% |
| Oct 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $29.76 | $28.98 | -2.6% | +7.6% | -5.5% | +0.8% | -1.9% | +3.3% |
| Aug 25 | SMBC Nikko | Maintains | Outperform → Outperform | — | $21.00 | $21.41 | +2.0% | +3.6% | -9.6% | -2.5% | -6.9% | -0.6% |
| Aug 9 | Credit Suisse | Maintains | Outperform → Outperform | — | $24.73 | $23.92 | -3.3% | -0.8% | -3.8% | -0.3% | +4.0% | +0.9% |
| Mar 16 | SMBC Nikko | Maintains | Outperform → Outperform | — | $20.18 | $21.41 | +6.1% | +12.8% | +7.2% | +3.4% | -9.6% | +3.8% |
| Mar 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.79 | $21.79 | +0.0% | -0.9% | -2.8% | -3.2% | -2.0% | +0.6% |
| Nov 10 | Credit Suisse | Maintains | Outperform → Outperform | — | $43.88 | $44.99 | +2.5% | -2.1% | +1.3% | -0.6% | +2.9% | -1.2% |
| Nov 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $46.02 | $45.30 | -1.6% | -1.3% | -1.0% | -1.2% | +0.7% | -0.5% |
| Sep 21 | JMP Securities | Maintains | Market Outperform → Outperform | — | $35.62 | $36.80 | +3.3% | +4.7% | -2.0% | +3.4% | -2.8% | -1.4% |
No insider trades available.
8-K · 8.01
!! High
Inhibrx Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Inhibrx Biosciences' ozekibart has cleared FDA acceptance for a BLA in unresectable/metastatic chondrosarcoma with an April 2027 decision deadline, supporting potential near-term approval and commercialization catalyst.
Jun 15
8-K
Inhibrx Biosciences, Inc. -- 8-K Filing
I cannot provide an analysis based on this filing summary, as it contains only administrative details (incorporation information, tax ID, address) with no material business development, transaction, or financial information relevant to investors.
Jun 3
8-K · 8.01
!! High
Inhibrx Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Inhibrx Biosciences updated its corporate presentation on April 21, 2026, indicating potential strategic communications or business developments for investors to review on its website.
Apr 21
8-K
Unknown — 8-K Filing
Inhibrx released FY2025 results, signaling operational progress that investors should evaluate against pipeline advancement, cash burn rate, and path to revenue generation for biotech valuation.
Mar 19
8-K · 7.01
! Medium
Inhibrx Biosciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Inhibrx Biosciences disclosed a presentation to investors detailing company updates and business summaries, typically delivered at conferences and investor meetings.
Feb 23
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 14
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Core Fund | 6,623 | $445K | Mar 2026 |
| 2 | Direxion Daily S&P Biotech Bull 3X Shares | 5,690 | $434K | Jan 2026 |
| 3 | Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF | 4,220 | $313K | Feb 2026 |
| 4 | SMALL CAP EQUITY FUND | 4,318 | $290K | Mar 2026 |
| 5 | Small Cap Index Fund | 4,203 | $283K | Mar 2026 |
| 6 | Virtus LifeSci Biotech Clinical Trials ETF | 3,540 | $270K | Jan 2026 |
| 7 | First Trust Active Factor Small Cap ETF | 1,440 | $107K | Feb 2026 |
| 8 | Meridian Small Cap Growth Fund | 96,915 | $69K | Mar 2026 |
| 9 | iShares Morningstar Small-Cap ETF | 1,890 | $33K | Jan 2026 |
| 10 | Global X Russell 2000 Covered Call ETF | 15,798 | $10K | Jan 2026 |
| 11 | Pacer WealthShield ETF | 112 | $9K | Jan 2026 |
| 12 | Russell 2000 Fund | 21 | $1K | Mar 2026 |
| 13 | Russell 2000 1.5x Strategy Fund | 12 | $807 | Mar 2026 |
| 14 | Knights of Columbus U.S. ALL CAP INDEX FUND | 132 | $0 | Jan 2026 |
Valuation
Market Cap
$1.44B
Enterprise Value
$1.42B
P/E (TTM)
-10.29x
Forward P/E
—
PEG Ratio
0.08x
P/B
180.29x
P/S
1108.51x
P/FCF
-11.10x
EV/EBITDA
—
Shares Out
15.5M
Financials (TTM)
Revenue
$1.3M
Net Income
-$140.1M
EBITDA
-$132.5M
Free Cash Flow
-$129.8M
Op Cash Flow
-$129.8M
EPS Basic
$-9.04
EPS Diluted
$-9.04
EPS Forward
$-7.83
Gross Margin
-91.0%
Op Margin
-10386.5%
Net Margin
-10773.5%
Balance Sheet
Total Assets
$146.5M
Total Liab.
$138.5M
Total Equity
$8.0M
Cash
$124.2M
LT Debt
$100.6M
Book Value/Sh
$0.52
Debt/Equity
13.39x
Current Ratio
3.93
Quick Ratio
3.93
Returns & Growth
ROE
-1752.2%
ROA
-95.6%
ROIC
-117.4%
Rev Growth YoY
+550.0%
EPS Growth YoY
-107.7%
Price Returns
2W
-10.5%
1M
-19.5%
3M
+40.3%
6M
+23.6%
12M
+672.2%
Technicals
52W High
$141.84
52W Low
$14.27
50d MA
$104.53
200d MA
$75.06
RSI (14)
32.90
ATR (14)
$6.37
Beta
1.83
Avg Volume
435K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:29pm
· Source: financialmodelingprep.com